Warburg Pincus Nears ₹1,800 Cr Deal for Maneesh Pharma's Key Medicine Brands

HEALTHCAREBIOTECH
Whalesbook Logo
AuthorKavya Nair|Published at:
Warburg Pincus Nears ₹1,800 Cr Deal for Maneesh Pharma's Key Medicine Brands
Overview

US private equity giant Warburg Pincus is nearing a deal to acquire Maneesh Pharmaceuticals' formulation business for up to ₹1,800 crore. The acquisition focuses on Maneesh's non-tuberculosis (non-TB) medicines portfolio, including prominent brands like Doxinate and Smyle Mouth Ulcer Gel. This move aligns with Warburg Pincus's broader strategy to consolidate and build a significant pharmaceutical platform within India.

Deal Nears Final Stages

Discussions for the deal have been ongoing for at least two years and are now in the final stages, with an exclusivity agreement in place. Warburg Pincus is reportedly set to acquire Maneesh Pharmaceuticals' portfolio of non-tuberculosis (non-TB) medicines for a sum between ₹1,600 crore and ₹1,800 crore.

Maneesh's Strong Brands

Maneesh Pharmaceuticals is known for its strong brands, including Smyle Mouth Ulcer Gel and key gynaecology products like Doxinate and Clofert. Doxinate, used to treat morning sickness, contributes approximately ₹110 crore in annual sales on its own. The company reported a moving annual turnover of ₹504 crore as of February 2026, showing a 6% growth rate.

Warburg's Expansion Strategy

The acquisition is a key part of Warburg Pincus's wider strategy to merge two to three India-focused pharmaceutical companies into a single platform. The firm is currently seeking experienced leadership for this new venture, with reports suggesting Rehan Khan, former head of Merck & Co. in India, could be considered. This follows Warburg's earlier efforts to acquire Integrace Health for approximately ₹1,200 crore, reinforcing its commitment to the Indian healthcare sector.

Disclaimer:This content is for informational purposes only and does not constitute financial or investment advice. Readers should consult a SEBI-registered advisor before making decisions. Investments are subject to market risks, and past performance does not guarantee future results. The publisher and authors are not liable for any losses. Accuracy and completeness are not guaranteed, and views expressed may not reflect the publication’s editorial stance.